PMD118 Comparison Of Epidermal Growth Factor Receptor (Egfr) Tested And Not-Tested Metastatic Non-Small Cell Lung Cancer (Mnsclc) Patient Cohorts In Europe  by Narayanan, S & Gallo, F
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A365
patients were conducted by cancer treating physicians in Germany/France/Spain/
Italy (EU4) and the UK; Data collection period was Jan-Dec 2013. Physicians 
were recruited from a geographically representative sample in each country. 
Approximately 10-25 eligible patients on usual care anti-cancer regimen were 
identified by each physician within the four-quarterly study observation-window. 
Physicians abstracted data on patient demographics, disease status, treatment 
patterns and biomarker status .The analysis focused on patients that were either 
tested (T) or not-tested (NT) for EGFRm in UK & EU4. Results: Approximately 
4800 mNSCLC patient-charts (UK~630/4EU~4170) were collected in 2013. 62%/62% 
were tested for EGFRm in the UK/4EU respectively. Mean age was: T-64yrs/NT-67yrs 
in both UK and EU4; proportion of patients who were male: T-56%/NT-64% in UK, 
T-61%/NT-78% in EU4. Proportion of patients who ‘never smoked’ was: T-29%/NT-9% 
in UK, T-23%/NT-12% in EU4. Time since disease diagnosis was: T-6mo/NT-10mo in 
UK, T-9mo/NT-9mo in EU4. Proportion of patients newly diagnosed: T-53%/NT-38% 
in UK, T-39%/NT-50% in EU4; % in relapse: T-24%/NT-50% in UK, T-32%/NT-19% in 
EU4. Proportion of patients with an ECOG score of > = 2 at the time of visit: T-4%/
NT-12% in UK, T-24%/NT-24% in EU4. ConClusions: Distinct differences appear 
to exist within mNSCLC cohorts based on the EGFRm test status (T/NT) and geog-
raphy (UK/EU4). This warrants further research to understand the drivers behind 
the observed patterns (including the dynamics of respective national healthcare 
systems, access to biomarker testing, and physicians’ perception of patient suitabil-
ity for EGFRm testing) and to facilitate optimal care delivery that could eventually 
lead to the utilization of targeted oncology therapeutics to alleviate patient burden 
and improve outcomes.
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objeCtives: Compare the characteristics of mCRC patients either tested or not for 
KRAS mutations in Europe in 2009 and 2013. Methods: A multi-country retrospec-
tive medical chart-review of mCRC patients were conducted by cancer treating phy-
sicians in Germany/France/Spain/Italy (EU4) and the UK; Data collection period was 
2009-2013. Physicians were recruited from a geographically representative sample 
in each country. Approximately 10-25 eligible patients on usual care anti-cancer 
regimen were identified by each physician within each of the four-quarterly study 
observation-windows in respective years. Physicians abstracted data on patient 
demographics, disease status, treatment patterns and biomarker status .The 
analysis focused on patients that were either tested (T) or not (NT) for KRAS muta-
tion in 2009 and 2013. Results: Approximately 2350 mCRC patient-charts (UK~300/
EU4~2050) were abstracted in both 2013 and 2009. Proportion of patients who were 
male in 2013 were: T-62%/NT-60% in both UK and EU4; a directional shift towards 
more male patients in UK and towards more female patients in EU4 was noted 
from 2009 to 2013. Mean age was: T-55yrs/NT-66yrs in UK and T-64yrs/NT-66yrs in 
EU4 in 2009, while T-67yrs/NT-68yrs in UK and T-66yrs/NT-72yrs on EU4 in 2013. 
Majority (UK:56%/EU4:47%) of KRASm-tested patients were follow-up patients in 
2009 while the majority (UK:57%/EU4:42%) had relapse-status in 2013. Proportion 
of patients with an ECOG score of > = 1 at the time of visit was: T-68%/NT-77% in 
UK, T-60%/NT-66% in EU4 in 2009; T-82%/NT-76% in UK, T-74%/NT-79% in EU4 in 
2013. ConClusions: Distinct differences appear to exist within mCRC cohorts 
based on the KRASm test status (T/NT), geography (UK/EU4) and the observation 
time-span (2009/2013). This warrants further research to understand the drivers 
behind the observed patterns and to facilitate optimal care deliverythat could even-
tually lead to the utilization of targeted oncology therapeutics to alleviate patient 
burden and improve outcomes.
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objeCtives: Prevalence of cardiovascular diseases is outsanding in Hungary. 
Incorrect data due to the inappropriate measurement of blood pressure and the 
inappropriate choice of the measurement tool cause a huge problem during clinical 
decision making. The aim of our exmination was to evaluate the nurses’ knowl-
edge on blood pressure measurement and analyse the precision of oscillometric 
blood pressure measurement compared to the mercurial blood pressure moni-
tor. Methods: In our quantitative, cross-sectional study 96 nurses completed one 
questionnaire with only closed-ended questions and one with only open-ended 
questions. During the experimental study we measured the blood pressure of 16 
patients with tremor, 12 patients with arrhythmia and 32 patients with hypertonia. 
We used Microsoft Office Excel 2002 software to carry out descriptive statistics, 
χ 2-test and two-sample t-test (p< 0.05). Results: We found no significant differ-
ence between the two questionnaire types (p= 0.261), but we did find significant 
difference in the participating nurses’ level of knowledge (p> 0.001). Comparing 
the systolic values of patients with tremor showed significant difference between 
the mercurial- and the oscillometric blood pressure measurements (p= 0,003). We 
found no significant difference in case of the diastolic measures (p< 0.05). In case 
of patients with high blood pressure we found no significant difference regarding 
systolic values (p= 0.067), but we did find significant difference regarding the dias-
tolic values (p= 0.044). In case of patients with cardiac arrhythmia, no significant 
difference can be detected between the two measurements regarding the systolic 
(p= 0.352) and diastolic values (p= 0.274). ConClusions: A necessary requirement 
of valid blood pressure measurement is to apply the appropriate blood pressure 
measurement protocol considering the influencing factors, and the application 
of aneroid blood pressure monitor (with approximately the same accuracy as the 
mercurial blood pressure monitor) with auscultation method.
mechanical ventilation≥ 96hours(n= 7); DRG-87.Respiratory insufficiency(n= 6); 
DRG-179.Inflammatory bowel diseases(n= 6); DRG-395.Red Blood Cells 
anomalies(n= 5), accounting for 215,414€ (29% of total). The economic value associ-
ated to whole admissions was 738,258€ . The most significant fluctuation of income 
within the same DRG was in the more frequent one: DRG-572(1,742€ -6,524€ ); and in 
the fifth DRG by frequency: DRG-395(3,394€ -15,124€ ). Differences are due to regional 
DRG monitoring. The higher economic values were associated to bowel, liver or 
bone marrow transplantation (DRGs480-481). ConClusions: This pool of evidence 
allows developing standardised pathways for early diagnosis and treatment that 
help improving patients’ care, increasing hospital efficiency and bed occupancy, 
reduce length of stay and improve measures for infection control.
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objeCtives: The aim of this research is to assess US Medicare methodologies for 
the reimbursement of medical devices in hospital inpatient and outpatient ser-
vices. Methods: A comprehensive literature search was conducted on PuBmed 
and US Department of Health and Human Services specific to Centers for Medicare 
and Medicaid Services (CMS). Results: CMS reimbursement structure is shaped by 
coverage, coding and payment arrangements with reimbursement playing a major 
role for commercially available devices and coding and coverage for devices under 
clinical studies. The payment mechanisms applied are defined by diagnosis related 
groups (DRG; hospital inpatient) and ambulatory payment classification (APC; hos-
pital outpatient) with an additional three separate short-term payment policies: 
new technology add on payments for in-patient services, transitional pass-through 
payments and new technology ambulatory payment classifications for outpatient 
services. Biannual reports are performed on existing and new policies for both inpa-
tient and outpatient provisions with updates on the reimbursement system retro-
spectively from 2-3 years prior to year of implementation. A case example in cardiac 
resynchronization therapies (CRT) in both inpatient and outpatient setting is used 
to illustrate the reimbursement mechanisms used by US Medicare. Medicare used 
a new technology add-on payment for 1 year (up to $16,262 supplemental funding) 
in addition to DRG payment (ranging from $81,950 to $104,092). To compare volume 
and estimated payments of CRT devices in the outpatient setting (2,358 outpatient 
compared to 21,920 inpatient) a separation of APC codes (with intent to create a 
new APC code) was conducted. The creation of a new APC code was refused with 
further restructuring of existing codes. ConClusions: The results show regular 
and systematic collection of data to revise tariffs each year act as the main feature 
to allow for new medical technology to be accessible.
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objeCtives: To assess the patterns of use of tests to monitor disease activity/
progression among patients currently treated with disease modifying treatments 
(DMTs) for RRMS in EU. Methods: A multi-center retrospective chart-review study 
of MS patients was conducted in EU (UK/France/Germany/Italy/Spain) to collect de-
identified data on diagnosis, clinical status, and disease management approaches. 
Healthcare providers (mostly neurologists) were screened for duration of practice 
(≥ 3yrs) and patient volume (≥ 15 MS patients/mo) and recruited from a large panel 
to be geographically representative in each country. Medical charts of next 10 con-
secutive MS patients were abstracted by each HCP. RRMS patients currently on DMTs 
were analyzed. Results: 1465 eligible RRMS patients treated with DMTs (UK:254, 
France:315, Germany:303, Italy:318, Spain:275) were included in this analysis. Time 
between MS diagnosis and initiation with a DMT was 8.3mo (range: 5.3(Germany) 
- 11.0(UK)). Proportion of patients on their first/second/third-or-more line DMT dur-
ing the study was 60%/29%/11%. Distribution of use of key tests to monitor disease 
activity/progression varied among RRMS patients on different lines of DMT (1st-
line/2nd-line/3rd-line-or-more: % patients assessed): Expanded Disability Status 
Scale (EDSS): 85/89/89; Neurological exam: 81/89/88; Gadolinium MRI: 59/70/80; T2 
MRI: 58/68/79; T1 MRI: 51/56/70; Brain atrophy: 11/18/24; Ambulation index: 11/15/23. 
For patients on 1st-line/2nd-line/3rd-line-or-more DMTs, mean # of Gd-enhanced 
lesions and # of T2 lesions were1.3/1.4/2.0 and 8.6/11.5/14.3 respectively. Proportion 
of patients with unknown Gd-enhanced lesions and unknown T2 lesions were (1st-
line/2nd-line/3rd-line-or-more): 35/27/22 and 33/28/26 respectively. ConClusions: 
Neurological exam and EDSS were used among most patients, while prevalence 
of use of other tests varied and increased with patient progression through treat-
ment lines. At least one-fourth and one-fifth of patients across treatment lines had 
unknown T2 and gd-enhanced lesions respectively. Observed practice patterns may 
warrant further scrutiny to optimize care delivery and therapeutic interventions 
to alleviate disease burden.
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objeCtives: Compare the characteristics of mNSCLC patients either tested or 
not for Human Epidermal Growth Factor Receptor 2 mutation (EGFRm/HER2) in 
Europe. Methods: A multi-country retrospective medical chart-review of mNSCLC 
